Hsu, Shih-Jer; Enkhzaya, Sukhee; Lin, You-Yu; Tseng, Tai-Chung; Khosbayar, Tulgaa; Tsai, Cheng-Hsueh; Wang, Tzu-San; Enkhtuya, Damba; Ivshinkhorol, Dogsom; Naranzul, Nyamsuren; Jargalsaikhan, Badarch; Amarsanaa, Jazag; Baatarkhuu, Oidov; Kao, Jia-Horng published the artcile< Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients>, Synthetic Route of 58-97-9, the main research area is chronic hepatitis C ledipasvir sofosbuvir NS5A Mongolia; Chronic hepatitis C; Ledipasvir; Mongolia; Resistance-associated substitution; Sofosbuvir.
We investigated the effectiveness of ledipasvir/sofosbuvir and the impact of resistance-associated substitutions on the treatment outcome in Mongolian chronic hepatitis C patients. Patients with genotype (GT) 1b HCV infection were prospectively enrolled in Mongolia and treated with LDV/SOF for 12 wk. The proportion of pre-treatment NS5A Y93H RAS in viral quasispecies was measured with next-generation sequencing. The endpoint of LDV/SOF effectiveness was sustained virol. response at post-treatment week 12 (SVR12). A total of 94 CHC patients were evaluated. The baseline Y93H proportion was <1% in 74 patients, 1-15% in 7, 15-50% in 2, and ≥50% in 11. All patients completed 12-wk LDV/SOF treatment and the SVR rate was 90.4%. The rate of failure to achieve SVR12 for patients with Y93H < 1%, 1-15%, and ≥15% were 0%, 14.3%, and 61.5%, resp. (p for trend = 0.001). In univariable anal., older age, baseline alanine transaminase level <40 U/mL, and a higher proportion of Y93H were associated with treatment failure. In multivariable anal., only a higher proportion of Y93H was associated with treatment failure (p = 0.022). LDV/SOF therapy achieves a high SVR rate in Mongolian CHC GT1b patients without baseline Y93H RAS. A higher proportion of Y93H may severely undermine the effectiveness of LDV/SOF. Journal of the Formosan Medical Association published new progress about Aging, animal. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Synthetic Route of 58-97-9.
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem